Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Cecchini, Michael, Sznol, Mario, Seropian, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372324/
https://www.ncbi.nlm.nih.gov/pubmed/25806109
http://dx.doi.org/10.1186/s40425-015-0054-4
_version_ 1782363161147473920
author Cecchini, Michael
Sznol, Mario
Seropian, Stuart
author_facet Cecchini, Michael
Sznol, Mario
Seropian, Stuart
author_sort Cecchini, Michael
collection PubMed
description Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.
format Online
Article
Text
id pubmed-4372324
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43723242015-03-25 Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant Cecchini, Michael Sznol, Mario Seropian, Stuart J Immunother Cancer Case Report Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD. BioMed Central 2015-03-24 /pmc/articles/PMC4372324/ /pubmed/25806109 http://dx.doi.org/10.1186/s40425-015-0054-4 Text en © Cecchini et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Cecchini, Michael
Sznol, Mario
Seropian, Stuart
Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
title Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
title_full Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
title_fullStr Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
title_full_unstemmed Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
title_short Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
title_sort immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372324/
https://www.ncbi.nlm.nih.gov/pubmed/25806109
http://dx.doi.org/10.1186/s40425-015-0054-4
work_keys_str_mv AT cecchinimichael immunetherapyofmetastaticmelanomadevelopingafterallogeneicbonemarrowtransplant
AT sznolmario immunetherapyofmetastaticmelanomadevelopingafterallogeneicbonemarrowtransplant
AT seropianstuart immunetherapyofmetastaticmelanomadevelopingafterallogeneicbonemarrowtransplant

Ejemplares similares